Simcere Pharmaceutical Group Limited (HKG:2096)
Hong Kong
· Delayed Price · Currency is HKD 8.66
+0.26 (3.10%)
Apr 3, 2025, 4:08 PM HKT
HKG:2096 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 6,635 | 6,608 | 6,324 | 5,000 | 4,509 | Upgrade
|
| Revenue Growth (YoY) | 0.41% | 4.49% | 26.49% | 10.89% | -10.48% | Upgrade
|
| Cost of Revenue | 1,311 | 1,624 | 1,327 | 1,080 | 899.93 | Upgrade
|
| Gross Profit | 5,325 | 4,984 | 4,997 | 3,920 | 3,609 | Upgrade
|
| Selling, General & Admin | 3,037 | 2,856 | 2,849 | 2,403 | 1,982 | Upgrade
|
| Research & Development | 1,410 | 1,563 | 1,728 | 1,417 | 1,142 | Upgrade
|
| Other Operating Expenses | -251.57 | -144.62 | -172.81 | -149.51 | -114.96 | Upgrade
|
| Operating Expenses | 4,189 | 4,273 | 4,390 | 3,686 | 3,009 | Upgrade
|
| Operating Income | 1,136 | 710.84 | 606.34 | 233.33 | 599.91 | Upgrade
|
| Interest Expense | -69.56 | -34.57 | -34.41 | -70.85 | -133.73 | Upgrade
|
| Interest & Investment Income | 39.23 | 54.96 | 59.87 | 68.29 | 26.25 | Upgrade
|
| Earnings From Equity Investments | 2.16 | 7.84 | 0.19 | -44.19 | -14.27 | Upgrade
|
| Currency Exchange Gain (Loss) | -20.87 | -13.28 | -57.22 | 116.01 | -46.23 | Upgrade
|
| EBT Excluding Unusual Items | 1,087 | 725.79 | 574.78 | 302.6 | 431.94 | Upgrade
|
| Gain (Loss) on Sale of Investments | -266.25 | -744.82 | 113.11 | 697.19 | 473.9 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.5 | 791.92 | -10.57 | 402.02 | -1.81 | Upgrade
|
| Asset Writedown | - | -6.87 | - | - | - | Upgrade
|
| Legal Settlements | 0.9 | -25.99 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | 208.94 | - | -98.94 | Upgrade
|
| Pretax Income | 819.88 | 740.04 | 886.25 | 1,402 | 805.09 | Upgrade
|
| Income Tax Expense | 86.71 | 26.09 | -40.48 | -97.12 | 140.8 | Upgrade
|
| Earnings From Continuing Operations | 733.17 | 713.95 | 926.73 | 1,499 | 664.29 | Upgrade
|
| Minority Interest in Earnings | - | 0.81 | 4.14 | 8.18 | 5.25 | Upgrade
|
| Net Income | 733.17 | 714.76 | 930.87 | 1,507 | 669.53 | Upgrade
|
| Net Income to Common | 733.17 | 714.76 | 930.87 | 1,507 | 669.53 | Upgrade
|
| Net Income Growth | 2.57% | -23.22% | -38.23% | 125.10% | -33.29% | Upgrade
|
| Shares Outstanding (Basic) | 2,513 | 2,609 | 2,611 | 2,609 | 2,393 | Upgrade
|
| Shares Outstanding (Diluted) | 2,520 | 2,609 | 2,620 | 2,611 | 2,393 | Upgrade
|
| Shares Change (YoY) | -3.40% | -0.45% | 0.34% | 9.14% | 2.03% | Upgrade
|
| EPS (Basic) | 0.29 | 0.27 | 0.36 | 0.58 | 0.28 | Upgrade
|
| EPS (Diluted) | 0.29 | 0.27 | 0.36 | 0.58 | 0.28 | Upgrade
|
| EPS Growth | 7.41% | -24.26% | -38.29% | 106.46% | -34.61% | Upgrade
|
| Free Cash Flow | - | -332.13 | 1,011 | -411.46 | -256.11 | Upgrade
|
| Free Cash Flow Per Share | - | -0.13 | 0.39 | -0.16 | -0.11 | Upgrade
|
| Dividend Per Share | 0.160 | 0.160 | 0.160 | 0.150 | 0.150 | Upgrade
|
| Dividend Growth | - | - | 6.67% | - | - | Upgrade
|
| Gross Margin | 80.25% | 75.43% | 79.01% | 78.40% | 80.04% | Upgrade
|
| Operating Margin | 17.12% | 10.76% | 9.59% | 4.67% | 13.31% | Upgrade
|
| Profit Margin | 11.05% | 10.82% | 14.72% | 30.14% | 14.85% | Upgrade
|
| Free Cash Flow Margin | - | -5.03% | 15.99% | -8.23% | -5.68% | Upgrade
|
| EBITDA | 1,350 | 925.12 | 815.38 | 422.45 | 758.55 | Upgrade
|
| EBITDA Margin | 20.35% | 14.00% | 12.89% | 8.45% | 16.82% | Upgrade
|
| D&A For EBITDA | 214.29 | 214.29 | 209.04 | 189.12 | 158.63 | Upgrade
|
| EBIT | 1,136 | 710.84 | 606.34 | 233.33 | 599.91 | Upgrade
|
| EBIT Margin | 17.12% | 10.76% | 9.59% | 4.67% | 13.31% | Upgrade
|
| Effective Tax Rate | 10.58% | 3.52% | - | - | 17.49% | Upgrade
|
Updated Sep 27, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.